Last reviewed · How we verify

Chronic sialorrhea — Treatment Landscape & Competitive Intelligence

Chronic sialorrhea (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic sialorrhea, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Xeomin INCOBOTULINUMTOXINA Merz Pharms Acetylcholine Release Inhibitor [EPC] 2015-01-01
Myobloc RIMABOTULINUMTOXINB Elan Pharm Acetylcholine Release Inhibitor [EPC] 2009-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Elan Pharm · 1 drug in Chronic sialorrhea
  2. Merz Pharms · 1 drug in Chronic sialorrhea

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic sialorrhea:

Cite this brief

Drug Landscape (2026). Chronic sialorrhea — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-sialorrhea. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing